In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Progenics Pharmaceuticals Inc.

www.progenics.com

Latest From Progenics Pharmaceuticals Inc.

Deal Watch: Another Delay For Roche/Spark, While FTC Ups AbbVie/Allergan Merger Scrutiny

Tender deadline for Roche acquisition of Spark pushed back to 30 October; 21.4% of Spark shares tendered so far. Vertex further diversifies with fourth deal of 2019 – an RNA-targeted collaboration with Ribometrix.

Deals M & A

Lantheus Buys Progenics To Combine Radiopharmaceuticals With Precision Diagnostics

Lantheus says the all-stock drug-diagnostics deal brings together complementary portfolios of ultrasound and radiopharmaceutical diagnostics with oncology therapeutics.

Commercial Deals

Medicare New Technology Add-On Payment Awards For Hospital Drugs On The Rise

Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011. 

Medicare Reimbursement

Boost For Chi-Med As Phase III NET Study Stopped Early On PFS Benefit

Chi-Med is setting a course straight for the Chinese FDA after its targeted therapy hit its PFS target ahead of schedule in neuroendocrine tumors.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Gastrointestinal
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Progenics Pharmaceuticals Inc.
  • Senior Management
  • David W Mims, Interim CEO
    Patrick Fabbio, SVP, CFO
    Asha Das, MD, CMO
    Huw Jones, VP, Conmmercial
  • Contact Info
  • Progenics Pharmaceuticals Inc.
    Phone: (646) 975-2500
    One World Trade Center
    47th Fl. Ste. J
    New York, NY 10007
    USA
UsernamePublicRestriction

Register